Paid Clinical Trials - 82,000 Members & Growing

  • Sponsored Links
  • About Us
  • Auto-Updates
  • FAQ's
  • Quick Start Guide
www.GlobalTestMarket.com

 

Find Paid Clinical Trials Join Paid Clinical Trials ...

PaidClinicalTrials.org is a registry of compensated and uncompensated, federally and privately supported clinical trials conducted in the United States and around the world. Here you will find information about a trial's purpose, who may participate, locations, and phone numbers.

 

Find Paid Clinical Trials Clinical Trial Seekers - PCT is a public service, sponsor supported, clinical trial database that may be accessed by the general public at no charge in accordance with our terms of service use.

Clinical trials are added and removed each day on a 30 day rotation. For accuracy - We only list clinical trials that have been reported to these government agencies in the last 30 days:

 

U.S. National Library of Medicine,
U.S. Department of Health & Human Services
U.S. National Institutes of health Services.







Paid Clinical Trials - Auto Update Service

If you would like to receive timely and important notifications about new clinical trials in your area please fill out this short form. There is never any cost for our notification services. We value your privacy, your email address and member information is NEVER shared!

*  Your Email Address:
*  Preferred Format:
    Title:
    First Name:
    Country:
    State (US):
    City (UK):
    Territory (AU):

Tips for Finding Clinical Trials

 

One of the toughest and most-time consuming parts for medical research staff conducting the clinical trials is actually finding volunteers willing to participate. Research staff are looking for you! There are numerous ways to identify clinical trials looking for healthy human volunteers.

 

Trials are actively conducted by hospitals, universities, foundations, and contract research organizations (CROs, firms that conduct studies for big pharmaceutical and biotechnology companies). According to CISCRP, nearly 40% of these clinical trials can be learned about through media such as tv, radio, or printed ads. While finding studies through tv and radio ads might be difficult, you can actively scour the wanted section of your local newspapers to find trials.

Most local research clinics run ads for volunteers in the local newspaper, employment papers, on TV, and on the radio. They also post ads on Craigslist and on their own websites. Call them up as soon as you see something of interest. If the study is no longer recruiting volunteers, they might enter you in there database for future study participation.

 

Look up local research clinics in your phone book and ask (a) if they have any studies openly recruiting healthy volunteers and (b) if you could be entered into their volunteer database.

College campuses and major universities with research hospitals are also great places to find clinical trial. Schools of medicine, dentistry, and nursing, along with departments of psychology, sociology, and communications, at local universities, are always looking for willing volunteers for their experiments. Perform an internet search for the hospitals, schools, and departments on nearby campuses, then look for any section concerning clinical trials or research volunteers.


When searching for clinical trials on our website you will click on a Clinical Trial Information sheet like this example. Find Paid Clinical Trials Example Information Sheet. The first thing you should do is to see if the clinical trial is right for you. You can do this by quickly scanning the headings of the information sheet. These headings are highlighted on the left by blue icons as follows:


  >> Status of the Clinical Trial (This will appear at the top in red or green)


Purpose - This will briefly let you know about the clinical trial and how it is conducted.


Eligibility - This tells you age, gender and health status information. If you do not meet these eligibility requirement you should move to another clinical trial.


Contacts and Locations - This will list the locations the clinical trial is being conducted and it will usually list the contact person to call. Note - Even if your location is not listed you should call the clinical trial investigator. Sometimes their locations have not been updated or they are willing to pay time and travel expenses.


More Information - This will often give alternative contact people and other pertinent information about the trial.

These headings appear on the left side of the information sheet and are fairly self explanatory. Doing this will help you to quickly evaluate if the clinical trial is right for you.

 


 

Paid Clinical Trials Searching Tips

 

Paid Clinical Trials Check the Conditions Category - If you only search the "Locations" directory you are missing out on a lot of clinical trials. Trials that are listed by "Condition" usually have multiple locations and can add new locations as the study moves forward.

 

Paid Clinical Trials Register Your Profile with us. - You can post your location and condition in our personal clinical trials directory for FREE. This helps the research recruiters find you when the right trial becomes available. Register for Clinical Trials Here.

 

Paid Clinical Trials Call the Clinical Trial Recruiters - At the bottom of all the information sheets you will see a "Contact Information" heading. Many clinical trials can be conducted in remote locations and the recruiters can help you.

 

Paid Clinical Trials Subscribe to our Auto Update Service - By subscribing to our Auto Update Service you will receive automated emails informing you when new trials have opened in your area.


Browse Locations ... United States» ... Nevada» ... Henderson







  • Conditions:   Bladder Adenocarcinoma;   Bladder Mixed Adenocarcinoma;   Bladder Small Cell Carcinoma;   Bladder Squamous Cell Carcinoma;   Chromophobe Renal Cell Carcinoma;   Infiltrating Bladder Lymphoepithelioma-Like Carcinoma;   Infiltrating Bladder Urothelial Carcinoma;   Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant;   Infiltrating Bladder Urothelial Carcinoma With Giant Cells;   Infiltrating Bladder Urothelial Carcinoma, Nested Variant;   Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant;   Kidney Medullary Carcinoma;   Large Cell Neuroendocrine Carcinoma;   Metastatic Bladder Carcinoma;   Metastatic Bladder Large Cell Neuroendocrine Carcinoma;   Metastatic Bladder Small Cell Neuroendocrine Carcinoma;   Metastatic Bladder Squamous Cell Carcinoma;   Metastatic Infiltrating Bladder Urothelial Carcinoma, Lipid-Cell Variant;   Metastatic Kidney Medullary Carcinoma;   Metastatic Malignant Genitourinary System Neoplasm;   Metastatic Penile Carcinoma;   Metastatic Plasmacytoid Urothelial Carcinoma;   Metastatic Prostate Small Cell Carcinoma;   Metastatic Sarcomatoid Renal Cell Carcinoma;   Metastatic Sarcomatoid Urothelial Carcinoma;   Papillary Renal Cell Carcinoma;   Sarcomatoid Renal Cell Carcinoma;   Stage IV Bladder Cancer AJCC v8;   Stage IV Penile Cancer AJCC v8;   Stage IV Prostate Cancer AJCC v8;   Stage IV Renal Cell Cancer AJCC v8;   Stage IVA Bladder Cancer AJCC v8;   Stage IVA Prostate Cancer AJCC v8;   Stage IVB Bladder Cancer AJCC v8;   Stage IVB Prostate Cancer AJCC v8;   Testicular Leydig Cell Tumor;   Testicular Sertoli Cell Tumor
    Interventions:   Drug: Cabozantinib;   Drug: Cabozantinib S-malate;   Biological: Ipilimumab;   Biological: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Deleterious BRCA1 Gene Mutation;   Deleterious BRCA2 Gene Mutation;   Loss of Heterozygosity;   Lung Non-Small Cell Squamous Carcinoma;   Recurrent Large Cell Lung Carcinoma;   Recurrent Lung Adenocarcinoma;   Recurrent Lung Non-Small Cell Carcinoma;   Recurrent Non-Squamous Non-Small Cell Lung Carcinoma;   Stage IV Lung Cancer AJCC v8;   Stage IVA Lung Cancer AJCC v8;   Stage IVB Lung Cancer AJCC v8
    Intervention:   Drug: Rucaparib
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Malignant Neoplasm
    Interventions:   Drug: Dexamethasone;   Other: Placebo;   Other: Questionnaire;   Other: Quality-of-Life Assessment;   Drug: Everolimus
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Lung Non-Squamous Non-Small Cell Carcinoma;   PD-L1 Positive;   Stage IIIB Lung Cancer AJCC v8;   Stage IVA Lung Cancer AJCC v8
    Interventions:   Drug: Carboplatin;   Biological: Pembrolizumab;   Drug: Pemetrexed
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Stage III Distal Bile Duct Cancer AJCC v8;   Stage III Gallbladder Cancer AJCC v8;   Stage III Intrahepatic Cholangiocarcinoma AJCC v8;   Stage IIIA Distal Bile Duct Cancer AJCC v8;   Stage IIIA Gallbladder Cancer AJCC v8;   Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8;   Stage IIIB Distal Bile Duct Cancer AJCC v8;   Stage IIIB Gallbladder Cancer AJCC v8;   Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8;   Stage IV Distal Bile Duct Cancer AJCC v8;   Stage IV Gallbladder Cancer AJCC v8;   Stage IV Intrahepatic Cholangiocarcinoma AJCC v8;   Stage IVA Gallbladder Cancer AJCC v8;   Stage IVB Gallbladder Cancer AJCC v8;   Unresectable Extrahepatic Bile Duct Carcinoma;   Unresectable Gallbladder Carcinoma;   Unresectable Intrahepatic Cholangiocarcinoma
    Interventions:   Drug: Cisplatin;   Drug: Gemcitabine Hydrochloride;   Drug: Nab-paclitaxel
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   CCND1/IGHG1 Fusion Negative;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   t(11;14) Negative
    Interventions:   Drug: Ibrutinib;   Biological: Obinutuzumab;   Other: Quality-of-Life Assessment;   Drug: Venetoclax
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acral Lentiginous Melanoma;   Clinical Stage III Cutaneous Melanoma AJCC v8;   Clinical Stage IV Cutaneous Melanoma AJCC v8;   Mucosal Melanoma;   Pathologic Stage III Cutaneous Melanoma AJCC v8;   Pathologic Stage IIIA Cutaneous Melanoma AJCC v8;   Pathologic Stage IIIB Cutaneous Melanoma AJCC v8;   Pathologic Stage IIIC Cutaneous Melanoma AJCC v8;   Pathologic Stage IIID Cutaneous Melanoma AJCC v8;   Pathologic Stage IV Cutaneous Melanoma AJCC v8
    Interventions:   Biological: Pembrolizumab;   Procedure: Therapeutic Conventional Surgery
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Endometrial Undifferentiated Carcinoma;   Endometrioid Adenocarcinoma;   Recurrent Endometrial Serous Adenocarcinoma;   Recurrent Uterine Corpus Carcinoma;   Stage IV Uterine Corpus Cancer AJCC v7;   Stage IVA Uterine Corpus Cancer AJCC v7;   Stage IVB Uterine Corpus Cancer AJCC v7
    Interventions:   Drug: Cediranib Maleate;   Other: Laboratory Biomarker Analysis;   Drug: Olaparib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Metastatic Renal Cell Carcinoma;   Renal Cell Carcinoma Associated With Xp11.2 Translocations/TFE3 Gene Fusions;   Stage III Renal Cell Cancer AJCC v8;   Stage IV Renal Cell Cancer AJCC v8;   TFE3 Gene Translocation;   TFEB Gene Translocation;   Unresectable Renal Cell Carcinoma
    Interventions:   Drug: Axitinib;   Biological: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Atypical Carcinoid Tumor;   Carcinoid Tumor;   Digestive System Neuroendocrine Neoplasm;   Enterochromaffin Cell Serotonin-Producing Pancreatic Neuroendocrine Tumor;   Functional Pancreatic Neuroendocrine Tumor;   Intermediate Grade Lung Neuroendocrine Neoplasm;   Low Grade Lung Neuroendocrine Neoplasm;   Lung Atypical Carcinoid Tumor;   Lung Carcinoid Tumor;   Metastatic Digestive System Neuroendocrine Tumor G1;   Neuroendocrine Neoplasm;   Nonfunctional Pancreatic Neuroendocrine Tumor;   Pancreatic Neuroendocrine Tumor;   Stage IIIA Digestive System Neuroendocrine Tumor AJCC v7;   Stage IIIB Digestive System Neuroendocrine Tumor AJCC v7;   Stage IV Digestive System Neuroendocrine Tumor AJCC v7
    Interventions:   Drug: Cabozantinib S-malate;   Other: Laboratory Biomarker Analysis;   Other: Placebo;   Other: Quality-of-Life Assessment
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Stage II Bladder Urothelial Carcinoma AJCC v6 and v7;   Stage III Bladder Urothelial Carcinoma AJCC v6 and v7
    Interventions:   Other: Clinical Observation;   Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab;   Other: Pharmacological Study;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Caregiver;   Cognitive Impairment;   Stage 0 Colorectal Cancer AJCC v6 and v7;   Stage I Colorectal Cancer AJCC v6 and v7;   Stage II Colorectal Cancer AJCC v7;   Stage IIA Colorectal Cancer AJCC v7;   Stage IIB Colorectal Cancer AJCC v7;   Stage IIC Colorectal Cancer AJCC v7;   Stage III Colorectal Cancer AJCC v7;   Stage IIIA Colorectal Cancer AJCC v7;   Stage IIIB Colorectal Cancer AJCC v7;   Stage IIIC Colorectal Cancer AJCC v7
    Interventions:   Drug: Ibuprofen;   Other: Placebo;   Other: Questionnaire Administration
    Sponsors:   Gary Morrow;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Stage IIIB Non-Small Cell Lung Cancer;   Stage IV Non-small Cell Lung Cancer
    Interventions:   Drug: Naloxegol;   Other: Placebo;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Stage III Cutaneous Melanoma AJCC v7;   Stage IIIA Cutaneous Melanoma AJCC v7;   Stage IIIB Cutaneous Melanoma AJCC v7;   Stage IIIC Cutaneous Melanoma AJCC v7;   Stage IV Cutaneous Melanoma AJCC v6 and v7;   Unresectable Melanoma
    Interventions:   Biological: Ipilimumab;   Biological: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Node Positive HER2 Negative Breast Cancer
    Interventions:   Other: Placebo;   Drug: Aspirin
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   United States Department of Defense;   Bayer;   Canadian Cancer Trials Group
    Recruiting

  • Conditions:   Colon Adenocarcinoma;   DNA Repair Disorder;   Lynch Syndrome;   Stage III Colon Cancer AJCC v7;   Stage IIIA Colon Cancer AJCC v7;   Stage IIIB Colon Cancer AJCC v7;   Stage IIIC Colon Cancer AJCC v7
    Interventions:   Drug: Atezolizumab;   Drug: Fluorouracil;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Oxaliplatin;   Other: Quality-of-Life Assessment
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Lung Carcinoma
    Interventions:   Drug: Varenicline;   Drug: Placebo;   Other: Tobacco Cessation Counseling
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   Pfizer
    Recruiting

  • Conditions:   Acinar Cell Carcinoma;   Adenoid Cystic Carcinoma;   Adrenal Cortex Carcinoma;   Adrenal Gland Pheochromocytoma;   Anal Canal Neuroendocrine Carcinoma;   Anal Canal Undifferentiated Carcinoma;   Appendix Mucinous Adenocarcinoma;   Bartholin Gland Transitional Cell Carcinoma;   Bladder Adenocarcinoma;   Cervical Adenocarcinoma;   Cholangiocarcinoma;   Chordoma;   Colorectal Squamous Cell Carcinoma;   Desmoid-Type Fibromatosis;   Endometrial Transitional Cell Carcinoma;   Endometrioid Adenocarcinoma;   Esophageal Neuroendocrine Carcinoma;   Esophageal Undifferentiated Carcinoma;   Extrahepatic Bile Duct Carcinoma;   Fallopian Tube Adenocarcinoma;   Fallopian Tube Transitional Cell Carcinoma;   Fibromyxoid Tumor;   Gastric Neuroendocrine Carcinoma;   Gastric Squamous Cell Carcinoma;   Gastric Undifferentiated Carcinoma;   Gastrointestinal Stromal Tumor;   Giant Cell Carcinoma;   Intestinal Neuroendocrine Carcinoma;   Intrahepatic Cholangiocarcinoma;   Lung Carcinoid Tumor;   Lung Sarcomatoid Carcinoma;   Major Salivary Gland Carcinoma;   Malignant Odontogenic Neoplasm;   Malignant Peripheral Nerve Sheath Tumor;   Malignant Testicular Sex Cord-Stromal Tumor;   Metaplastic Breast Carcinoma;   Metastatic Malignant Neoplasm of Unknown Primary Origin;   Minimally Invasive Lung Adenocarcinoma;   Mixed Mesodermal (Mullerian) Tumor;   Mucinous Adenocarcinoma;   Mucinous Cystadenocarcinoma;   Nasal Cavity Adenocarcinoma;   Nasal Cavity Carcinoma;   Nasopharyngeal Carcinoma;   Nasopharyngeal Papillary Adenocarcinoma;   Nasopharyngeal Undifferentiated Carcinoma;   Oral Cavity Carcinoma;   Oropharyngeal Undifferentiated Carcinoma;   Ovarian Adenocarcinoma;   Ovarian Germ Cell Tumor;   Ovarian Mucinous Adenocarcinoma;   Ovarian Squamous Cell Carcinoma;   Ovarian Transitional Cell Carcinoma;   Pancreatic Acinar Cell Carcinoma;   Pancreatic Neuroendocrine Carcinoma;   Paraganglioma;   Paranasal Sinus Adenocarcinoma;   Paranasal Sinus Carcinoma;   Parathyroid Gland Carcinoma;   Pituitary Gland Carcinoma;   Placental Choriocarcinoma;   Placental-Site Gestational Trophoblastic Tumor;   Primary Peritoneal High Grade Serous Adenocarcinoma;   Pseudomyxoma Peritonei;   Rare Disorder;   Scrotal Squamous Cell Carcinoma;   Seminal Vesicle Adenocarcinoma;   Seminoma;   Serous Cystadenocarcinoma;   Small Intestinal Adenocarcinoma;   Small Intestinal Squamous Cell Carcinoma;   Spindle Cell Neoplasm;   Squamous Cell Carcinoma of the Penis;   Teratoma With Malignant Transformation;   Testicular Non-Seminomatous Germ Cell Tumor;   Thyroid Gland Carcinoma;   Tracheal Carcinoma;   Transitional Cell Carcinoma;   Ureter Adenocarcinoma;   Ureter Squamous Cell Carcinoma;   Urethral Adenocarcinoma;   Urethral Squamous Cell Carcinoma;   Vaginal Adenocarcinoma;   Vaginal Squamous Cell Carcinoma, Not Otherwise Specified;   Vulvar Carcinoma
    Interventions:   Procedure: Biospecimen Collection;   Biological: Ipilimumab;   Biological: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Stage III Renal Cell Cancer AJCC v7;   Stage IV Renal Cell Cancer AJCC v7;   Type 1 Papillary Renal Cell Carcinoma;   Type 2 Papillary Renal Cell Carcinoma;   Unresectable Renal Cell Carcinoma
    Interventions:   Drug: Cabozantinib;   Drug: Cabozantinib S-malate;   Drug: Crizotinib;   Drug: Savolitinib;   Drug: Sunitinib;   Drug: Sunitinib Malate
    Sponsors:   National Cancer Institute (NCI);   Canadian Cancer Trials Group
    Recruiting

  • Condition:   Breast Carcinoma
    Interventions:   Other: Health Education Program;   Other: Weight Loss Intervention
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   Division of Cancer Control;   NIH Biomarker, Imaging and Quality of Life Studies Funding Program (BIQSFP);   Canadian Cancer Trials Group
    Recruiting

  • Conditions:   Stage IB Non-Small Cell Lung Carcinoma AJCC v7;   Stage II Non-Small Cell Lung Cancer AJCC v7;   Stage IIA Non-Small Cell Lung Carcinoma AJCC v7;   Stage IIB Non-Small Cell Lung Carcinoma AJCC v7;   Stage IIIA Non-Small Cell Lung Cancer AJCC v7
    Intervention:   Biological: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Grade 1 Follicular Lymphoma;   Grade 2 Follicular Lymphoma;   Grade 3a Follicular Lymphoma;   Recurrent Follicular Lymphoma;   Refractory Follicular Lymphoma
    Interventions:   Drug: Bendamustine;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Doxorubicin Hydrochloride;   Drug: Lenalidomide;   Biological: Obinutuzumab;   Drug: Prednisone;   Drug: Umbralisib;   Drug: Vincristine;   Drug: Vincristine Sulfate
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Alveolar Rhabdomyosarcoma;   Botryoid-Type Embryonal Rhabdomyosarcoma;   Embryonal Rhabdomyosarcoma;   Rhabdomyosarcoma;   Sclerosing Rhabdomyosarcoma;   Spindle Cell Rhabdomyosarcoma;   Untreated Childhood Rhabdomyosarcoma
    Interventions:   Drug: Cyclophosphamide;   Biological: Dactinomycin;   Drug: Irinotecan Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Questionnaire Administration;   Radiation: Radiation Therapy;   Drug: Temsirolimus;   Drug: Vincristine Sulfate;   Drug: Vinorelbine
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Advanced Malignant Solid Neoplasm;   Bladder Carcinoma;   Breast Carcinoma;   Cervical Carcinoma;   Colon Carcinoma;   Colorectal Carcinoma;   Endometrial Carcinoma;   Esophageal Carcinoma;   Gastric Carcinoma;   Glioma;   Head and Neck Carcinoma;   Kidney Carcinoma;   Liver and Intrahepatic Bile Duct Carcinoma;   Lung Carcinoma;   Lymphoma;   Malignant Uterine Neoplasm;   Melanoma;   Ovarian Carcinoma;   Pancreatic Carcinoma;   Plasma Cell Myeloma;   Prostate Carcinoma;   Rectal Carcinoma;   Recurrent Bladder Carcinoma;   Recurrent Breast Carcinoma;   Recurrent Cervical Carcinoma;   Recurrent Colon Carcinoma;   Recurrent Colorectal Carcinoma;   Recurrent Esophageal Carcinoma;   Recurrent Gastric Carcinoma;   Recurrent Glioma;   Recurrent Head and Neck Carcinoma;   Recurrent Liver Carcinoma;   Recurrent Lung Carcinoma;   Recurrent Lymphoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Melanoma;   Recurrent Ovarian Carcinoma;   Recurrent Pancreatic Carcinoma;   Recurrent Plasma Cell Myeloma;   Recurrent Prostate Carcinoma;   Recurrent Rectal Carcinoma;   Recurrent Skin Carcinoma;   Recurrent Thyroid Gland Carcinoma;   Recurrent Uterine Corpus Carcinoma;   Refractory Lymphoma;   Refractory Malignant Solid Neoplasm;   Refractory Plasma Cell Myeloma;   Skin Carcinoma;   Thyroid Gland Carcinoma;   Uterine Corpus Cancer
    Interventions:   Drug: Adavosertib;   Drug: Afatinib;   Drug: Binimetinib;   Drug: Capivasertib;   Drug: Copanlisib;   Drug: Crizotinib;   Other: Cytology Specimen Collection Procedure;   Drug: Dabrafenib;   Drug: Dasatinib;   Drug: Defactinib;   Drug: Erdafitinib;   Drug: FGFR Inhibitor AZD4547;   Other: Laboratory Biomarker Analysis;   Drug: Larotrectinib;   Biological: Nivolumab;   Drug: Osimertinib;   Drug: Palbociclib;   Biological: Pertuzumab;   Drug: PI3K-beta Inhibitor GSK2636771;   Drug: Sapanisertib;   Drug: Sunitinib Malate;   Drug: Taselisib;   Drug: Trametinib;   Biological: Trastuzumab Emtansine;   Drug: Vismodegib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   ALK Gene Rearrangement;   ALK Gene Translocation;   ALK Positive;   Stage IB Non-Small Cell Lung Carcinoma AJCC v7;   Stage II Non-Small Cell Lung Cancer AJCC v7;   Stage IIA Non-Small Cell Lung Carcinoma AJCC v7;   Stage IIB Non-Small Cell Lung Carcinoma AJCC v7;   Stage IIIA Non-Small Cell Lung Cancer AJCC v7
    Interventions:   Other: Clinical Observation;   Drug: Crizotinib;   Other: Laboratory Biomarker Analysis
    Sponsors:   ECOG-ACRIN Cancer Research Group;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Lung Adenocarcinoma;   Lung Large Cell Carcinoma;   Stage IB Non-Small Cell Lung Carcinoma AJCC v7;   Stage IB Squamous Cell Lung Carcinoma AJCC v7;   Stage II Non-Small Cell Lung Cancer AJCC v7;   Stage II Squamous Cell Lung Carcinoma AJCC v7;   Stage IIA Non-Small Cell Lung Carcinoma AJCC v7;   Stage IIA Squamous Cell Lung Carcinoma AJCC v7;   Stage IIB Non-Small Cell Lung Carcinoma AJCC v7;   Stage IIB Squamous Cell Lung Carcinoma AJCC v7;   Stage IIIA Non-Small Cell Lung Cancer AJCC v7;   Stage IIIA Squamous Cell Lung Carcinoma AJCC v7
    Interventions:   Other: Clinical Observation;   Drug: Crizotinib;   Other: Cytology Specimen Collection Procedure;   Drug: Erlotinib Hydrochloride;   Biological: Nivolumab;   Other: Placebo
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   ALK Gene Rearrangement;   EGFR Exon 19 Deletion Mutation;   EGFR NP_005219.2:p.L858R;   Stage IB Non-Small Cell Lung Carcinoma AJCC v7;   Stage II Non-Small Cell Lung Cancer AJCC v7;   Stage IIA Non-Small Cell Lung Carcinoma AJCC v7;   Stage IIB Non-Small Cell Lung Carcinoma AJCC v7;   Stage IIIA Non-Small Cell Lung Cancer AJCC v7
    Interventions:   Other: Clinical Observation;   Drug: Erlotinib Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Placebo
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   BRAF NP_004324.2:p.V600X;   Metastatic Melanoma;   Recurrent Melanoma;   Stage III Cutaneous Melanoma AJCC v7;   Stage IIIA Cutaneous Melanoma AJCC v7;   Stage IIIB Cutaneous Melanoma AJCC v7;   Stage IIIC Cutaneous Melanoma AJCC v7;   Stage IV Cutaneous Melanoma AJCC v6 and v7;   Unresectable Cutaneous Melanoma
    Interventions:   Drug: Dabrafenib;   Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Other: Quality-of-Life Assessment;   Drug: Trametinib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia;   B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative;   BCR/ABL1 Fusion Protein Negative;   Untreated Adult Acute Lymphoblastic Leukemia
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Biological: Blinatumomab;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Daunorubicin Hydrochloride;   Drug: Dexamethasone;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Pegaspargase;   Drug: Prednisone;   Biological: Rituximab;   Drug: Vincristine Sulfate
    Sponsors:   National Cancer Institute (NCI);   Canadian Cancer Trials Group
    Recruiting

  • Conditions:   Recurrent Classic Hodgkin Lymphoma;   Refractory Classic Hodgkin Lymphoma
    Interventions:   Drug: Brentuximab Vedotin;   Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Pathologic Stage I Merkel Cell Carcinoma AJCC v8;   Pathologic Stage II Merkel Cell Carcinoma AJCC v8;   Pathologic Stage IIA Merkel Cell Carcinoma AJCC v8;   Pathologic Stage IIB Merkel Cell Carcinoma AJCC v8;   Pathologic Stage III Merkel Cell Carcinoma AJCC v8;   Pathologic Stage IIIA Merkel Cell Carcinoma AJCC v8;   Pathologic Stage IIIB Merkel Cell Carcinoma AJCC v8;   Resected Mass
    Interventions:   Other: Best Practice;   Biological: Pembrolizumab;   Radiation: Radiation Therapy
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Stage II Breast Cancer;   Stage IIIA Breast Cancer
    Interventions:   Procedure: Axillary Lymph Node Dissection (ALND);   Radiation: Nodal Radiation Therapy;   Radiation: Axillary Radiation Therapy
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   Canadian Cancer Trials Group
    Recruiting

  • Conditions:   Estrogen Receptor-positive Breast Cancer;   HER2/Neu Negative;   Stage IV Breast Cancer AJCC v6 and v7
    Interventions:   Drug: Palbociclib;   Drug: Letrozole;   Drug: Fulvestrant;   Other: Questionnaire Administration;   Other: Quality-of-Life Assessment
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Lung Cancer
    Interventions:   Radiation: Standard Radiation Dose Therapy;   Drug: cisplatin;   Drug: etoposide;   Radiation: High Radiation Dose Therapy;   Drug: carboplatin
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
    Interventions:   Drug: BGB-3111;   Drug: Bendamustine;   Drug: Rituximab
    Sponsor:   BeiGene
    Recruiting

  • Condition:   Chronic Pain
    Interventions:   Device: Spinal cord stimulation (SCS);   Device: Dorsal root ganglion stimulation (DRG)
    Sponsor:   Abbott Medical Devices
    Recruiting

  • Conditions:   Recurrent Bladder Urothelial Carcinoma;   Stage 0a Bladder Urothelial Carcinoma AJCC v6 and v7;   Stage 0is Bladder Urothelial Carcinoma AJCC v6 and v7;   Stage I Bladder Urothelial Carcinoma AJCC v6 and v7
    Intervention:   Drug: Atezolizumab
    Sponsors:   National Cancer Institute (NCI);   Canadian Cancer Trials Group
    Recruiting

  • Condition:   Malignant Neoplasm
    Intervention:   Other: Cytology Specimen Collection Procedure
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Malocclusion
    Interventions:   Device: OrthoPulse 2.0;   Device: OrthoPulse 2.1;   Device: Invisalign 3.5 Day Wear;   Device: Fixed Orthodontic Appliances (Braces)
    Sponsor:   Biolux Research Ltd.
    Recruiting

  • Condition:   Childhood Absence Epilepsy
    Intervention:   Drug: Cannabidiol Oral Solution
    Sponsor:   INSYS Therapeutics Inc
    Recruiting

  • Condition:   Diabetes Mellitus, Type 2
    Interventions:   Device: CGM;   Device: SMBG
    Sponsor:   DexCom, Inc.
    Recruiting

  • Condition:   Atopic Dermatitis
    Interventions:   Drug: Tezepelumab;   Other: Placebo
    Sponsors:   Amgen;   AstraZeneca
    Recruiting

  • Condition:   Psoriasis
    Interventions:   Drug: Apremilast;   Other: Placebo
    Sponsor:   Celgene
    Recruiting

  • Condition:   Psoriasis
    Interventions:   Drug: Apremilast (CC-10004);   Other: Placebo
    Sponsor:   Celgene
    Recruiting

  • Condition:   Atopic Dermatitis
    Intervention:   Drug: Tralokinumab
    Sponsor:   LEO Pharma
    Recruiting

  • Conditions:   Overweight;   Obesity
    Interventions:   Drug: Semaglutide;   Drug: Placebo (semaglutide)
    Sponsor:   Novo Nordisk A/S
    Recruiting

  • Condition:   Diabetes Mellitus, Type 2
    Interventions:   Device: Dexcom G6 CGM System;   Device: Blood glucose meter
    Sponsors:   DexCom, Inc.;   Jaeb Center for Health Research
    Recruiting

  • Conditions:   Pruritus;   Prurigo Nodularis
    Interventions:   Drug: 5mg Serlopitant Tablets;   Drug: Placebo Tablets
    Sponsor:   Menlo Therapeutics Inc.
    Recruiting

  • Conditions:   Pruritus;   Prurigo Nodularis;   Atopic Dermatitis;   Psoriasis
    Intervention:   Drug: 5 mg Serlopitant Tablets
    Sponsor:   Menlo Therapeutics Inc.
    Recruiting

  • Conditions:   Hypogonadism;   Cardiovascular Diseases
    Interventions:   Drug: Testosterone;   Drug: Placebo
    Sponsors:   AbbVie;   Acerus Pharmaceuticals Corporation;   Allergan Sales, LLC;   Endo Pharmaceuticals;   Upsher-Smith Laboratories
    Recruiting

  • Conditions:   Open Angle Glaucoma;   Ocular Hypertension
    Interventions:   Drug: Brimonidine Tartrate Ophthalmic Suspension;   Drug: Brimonidine Tartrate Ophthalmic Solution
    Sponsor:   Sun Pharma Advanced Research Company Limited
    Recruiting

  • Condition:   Inflammation and Pain Associated With Ocular Surgery
    Interventions:   Drug: SDN-037;   Drug: Placebo
    Sponsor:   Sun Pharma Advanced Research Company Limited
    Recruiting

  • Condition:   Coronary Artery Disease
    Interventions:   Drug: High dose potent statin;   Drug: ACE-I (lisinopril) or ARB (losartan);   Drug: Aspirin;   Behavioral: Lifestyle Counseling;   Behavioral: Quality of Life Questionnaires
    Sponsors:   University of Florida;   United States Department of Defense
    Recruiting

  • Conditions:   Advanced Breast Cancer;   Metastatic Breast Cancer
    Intervention:   Other: non-interventional
    Sponsor:   Pfizer
    Recruiting

  • Conditions:   Squamous Cell Carcinoma of the Oral Cavity and Oropharynx;   Oral Mucositis
    Interventions:   Drug: SGX942;   Drug: Placebo
    Sponsor:   Soligenix
    Recruiting

  • Conditions:   Biphasic Mesothelioma;   Epithelioid Mesothelioma;   Stage I Pleural Malignant Mesothelioma AJCC v7;   Stage IA Pleural Malignant Mesothelioma AJCC v7;   Stage IB Pleural Malignant Mesothelioma AJCC v7;   Stage II Pleural Malignant Mesothelioma AJCC v7;   Stage III Pleural Malignant Mesothelioma AJCC v7
    Interventions:   Drug: Atezolizumab;   Drug: Cisplatin;   Procedure: Extrapleural Pneumonectomy;   Drug: Pemetrexed Disodium;   Procedure: Pleurectomy;   Radiation: Radiation Therapy
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Multiple Myeloma
    Interventions:   Drug: Ixazomib;   Drug: Lenalidomide;   Drug: Dexamethasone
    Sponsor:   Millennium Pharmaceuticals, Inc.
    Recruiting

  • Condition:   Diabetes Mellitus, Type 2
    Interventions:   Drug: Canagliflozin 100 mg;   Drug: Canagliflozin 300 mg;   Drug: Placebo
    Sponsor:   Janssen Research & Development, LLC
    Recruiting

  • Conditions:   Colorectal Adenocarcinoma;   Mismatch Repair Deficiency;   Stage IV Colorectal Cancer AJCC v7;   Stage IVA Colorectal Cancer AJCC v7;   Stage IVB Colorectal Cancer AJCC v7
    Interventions:   Drug: Atezolizumab;   Biological: Bevacizumab;   Drug: Fluorouracil;   Drug: Leucovorin Calcium;   Drug: Oxaliplatin;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Cardiac Rhythm Disorder
    Intervention:  
    Sponsor:   Medtronic
    Recruiting

  • Conditions:   Estrogen Receptor Negative;   HER2/Neu Negative;   Invasive Breast Carcinoma;   Progesterone Receptor Negative;   Stage 0 Breast Cancer AJCC v6 and v7;   Stage I Breast Cancer AJCC v7;   Stage IA Breast Cancer AJCC v7;   Stage IB Breast Cancer AJCC v7;   Stage II Breast Cancer AJCC v6 and v7;   Stage IIA Breast Cancer AJCC v6 and v7;   Stage IIB Breast Cancer AJCC v6 and v7;   Stage III Breast Cancer AJCC v7;   Stage IIIA Breast Cancer AJCC v7;   Stage IIIB Breast Cancer AJCC v7;   Stage IIIC Breast Cancer AJCC v7;   Triple-Negative Breast Carcinoma
    Interventions:   Other: Laboratory Biomarker Analysis;   Other: Patient Observation;   Biological: Pembrolizumab;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Radiation: Radiation Therapy
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Rectal Adenocarcinoma;   Stage II Rectal Cancer AJCC v7;   Stage III Rectal Cancer AJCC v7
    Interventions:   Drug: Capecitabine;   Drug: Fluorouracil;   Radiation: Intensity-Modulated Radiation Therapy;   Drug: Leucovorin Calcium;   Drug: Oxaliplatin;   Biological: Pembrolizumab;   Drug: Veliparib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Primary Breast Augmentation;   Primary Breast Reconstruction;   Revision Breast Augmentation;   Revision Breast Reconstruction
    Interventions:   Device: MemoryShape® Breast Implants;   Device: MemoryGel® Breast Implants;   Procedure: Other Aesthetic Surgery
    Sponsor:   Mentor Worldwide, LLC
    Recruiting

  • Conditions:   Adrenal Cortex Carcinoma;   Alveolar Soft Part Sarcoma;   Central Nervous System Neoplasm;   Childhood Clear Cell Sarcoma of Soft Parts;   Clear Cell Sarcoma of Soft Tissue;   Ewing Sarcoma;   Hepatoblastoma;   Hepatocellular Carcinoma;   MITF Positive;   Osteosarcoma;   Recurrent Adrenal Cortex Carcinoma;   Recurrent Alveolar Soft Part Sarcoma;   Recurrent Ewing Sarcoma;   Recurrent Hepatoblastoma;   Recurrent Hepatocellular Carcinoma;   Recurrent Malignant Central Nervous System Neoplasm;   Recurrent Malignant Solid Neoplasm;   Recurrent Osteosarcoma;   Recurrent Renal Cell Carcinoma;   Recurrent Rhabdomyosarcoma;   Recurrent Soft Tissue Sarcoma;   Recurrent Soft Tissue Sarcoma, Excluding Rhabdomyosarcoma;   Recurrent Thyroid Gland Medullary Carcinoma;   Refractory Ewing Sarcoma;   Refractory Malignant Central Nervous System Neoplasm;   Refractory Malignant Solid Neoplasm;   Refractory Osteosarcoma;   Refractory Rhabdomyosarcoma;   Refractory Soft Tissue Sarcoma;   Refractory Soft Tissue Sarcoma, Excluding Rhabdomyosarcoma;   Renal Cell Carcinoma;   Rhabdomyosarcoma;   Soft Tissue Sarcoma, Excluding Rhabdomyosarcoma;   Solid Neoplasm;   Thyroid Gland Medullary Carcinoma;   Wilms Tumor
    Interventions:   Drug: Cabozantinib;   Drug: Cabozantinib S-malate;   Other: Pharmacological Study
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Myelodysplastic Syndromes (MDS)
    Intervention:   Other: Therapeutic
    Sponsors:   National Heart, Lung, and Blood Institute (NHLBI);   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Epilepsy With Partial-onset Seizures
    Interventions:   Drug: Lacosamide;   Other: Placebo
    Sponsor:   UCB BIOSCIENCES, Inc.
    Recruiting

  • Condition:   Pulmonary Arterial Hypertension
    Intervention:   Drug: Opsumit (macitentan)
    Sponsor:   Actelion
    Recruiting

  • Conditions:   Schizophrenia;   Schizoaffective Disorder
    Interventions:   Behavioral: Cognitive Adaptation Training;   Behavioral: Community Treatment
    Sponsors:   The University of Texas Health Science Center at San Antonio;   Vanguard Research Group;   National Institute of Mental Health (NIMH)
    Recruiting

  • Condition:   Influenza A
    Interventions:   Drug: Pimodivir 600 mg;   Drug: Placebo;   Other: SOC Treatment
    Sponsor:   Janssen Research & Development, LLC
    Recruiting

PaidClinicalTrials.orgPaidClinicalTrials.org